Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

113 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-01

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, placebo controlled trial of dietary zinc and S-adenosylmethionine (SAMe) in otherwise healthy alcoholic US Veterans. The primary goal is to determine if either dietary zinc or S-adenosylmethionine (SAMe) can augment lung immune defenses in alcoholics and thereby decrease the risk of lung injury and infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of SAMe in Patients With Alcoholic Liver Disease

NCT00573313

Liver Disease, Alcoholic

COMPLETED PHASE3

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

NCT05548452

Liver Disease; Alcohol-Related Cirrhosis Alcohol Use Disorder

RECRUITING PHASE1/PHASE2

Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.

NCT03018236

Cocaine Addiction Alcohol Addiction

UNKNOWN PHASE4

Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

NCT02900352

Alcohol Use Disorder

COMPLETED PHASE3

Effectiveness of Zonisamide in Alcohol Dependent Veterans

NCT02368431

Alcohol Use Disorder

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alcohol abuse is a major burden on society and even more of a problem in the Veteran population. Chronic alcohol ingestion can have serious health consequences including pneumonia and acute lung injury, which can occur suddenly and without warning even in physically fit individuals without apparent signs of alcohol dependence. Therefore, it is vital for the health of our Veterans and indeed the entire population to identify effective treatments that can limit or even prevent these devastating consequences. The primary goal of this clinical research project is to determine if dietary zinc or supplements of the antioxidant S-adenosylmethionine (SAMe) can augment lung immune defenses in otherwise healthy alcoholics and thereby decrease the risk of lung injury and infection. There is already strong evidence from the investigators' experimental animal model that moderate daily alcohol ingestion for as little as six weeks causes oxidative stress and zinc deficiency in the lung. These derangements result insult in dysfunction of the alveolar macrophage, which is the resident immune cell, and predisposes animals to the development of pneumonia. Importantly, in this same animal model, the investigators found that adding either zinc or antioxidants to the diet prevents these problems and preserves lung health even during daily alcohol ingestion.

This project will translate basic findings in the animal model to the clinical setting and determine whether or not zinc or SAMe supplements are effective in humans who pathologically consume alcohol. This project will enroll Veterans seen at the Atlanta Veterans Hospital in the Substance Abuse Treatment Program (SATP). Participants will be evaluated by undergoing a procedure to obtain samples of fluid from their lungs, measure zinc levels, redox potential, and assess how well their alveolar macrophages respond to bacteria (by determining phagocytic capacity). After completion of the initial evaluation, the participants will be randomized to receive standard treatment (placebo), zinc supplements, dietary SAMe, or the combination of zinc and SAMe for 14 days. All subjects will be evaluated for two weeks as they undergo treatment. At the end of this two week period, measurements of lung zinc, redox potential and macrophage function will be repeated and compared between the two groups. The hypothesis is that both dietary zinc and SAM supplements will improve the immune function of the alveolar macrophage.

If this project is successful, it will lead to larger clinical trials to determine if either dietary zinc and/or SAMe supplements can be effective even in the acute clinical setting and improve outcomes in alcoholics who develop pneumonia or acute lung injury. Overall, both zinc and SAMe supplements are safe and inexpensive to provide, allowing these potential treatments to be easily implemented in the Veteran population as well as society in general. Given the significant burden of unhealthy alcohol use, the investigators need ways to limit the physical consequences of alcohol abuse while the investigators continue the efforts at public education and addiction treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo zinc and placebo SAMe

Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily

Group Type PLACEBO_COMPARATOR

Bronchoscopy

Intervention Type PROCEDURE

Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

Active zinc and placebo SAMe

Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily

Group Type ACTIVE_COMPARATOR

Bronchoscopy

Intervention Type PROCEDURE

Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

Zinc sulfate 220 mg once daily

Intervention Type DIETARY_SUPPLEMENT

Placebo zinc and active SAMe

Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily

Group Type ACTIVE_COMPARATOR

Bronchoscopy

Intervention Type PROCEDURE

Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

S-adenosylmethionine 400 mg twice daily

Intervention Type DIETARY_SUPPLEMENT

Active zinc and active SAMe

Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily

Group Type ACTIVE_COMPARATOR

Bronchoscopy

Intervention Type PROCEDURE

Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

Zinc sulfate 220 mg once daily

Intervention Type DIETARY_SUPPLEMENT

S-adenosylmethionine 400 mg twice daily

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bronchoscopy

Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

Intervention Type PROCEDURE

Zinc sulfate 220 mg once daily

Intervention Type DIETARY_SUPPLEMENT

S-adenosylmethionine 400 mg twice daily

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SAMe

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-60 years
* Active alcohol use disorder

Exclusion Criteria

* Any active and uncontrolled medical problem(s)
* Known zinc deficiency
* Primary substance of abuse something other than alcohol
* Current abnormal chest x-ray
* HIV-positive
* Any disorder of blood coagulation
* Currently on medical treatment with anti-coagulants, including:

* warfarin
* heparin
* direct thrombin inhibitors
* anti-platelet agents (other than Aspirin)
* Daily use of vitamins or other nutritional supplements (unless taking as treatment for alcohol use disorder)
* Renal impairment (GFR \< 60)
* Active bipolar disorder
* Active Parkinson's disease
* Current pregnancy
* Contraindication to treatment with zinc or S-adenosylmethionine
* Inability to give informed consent (i.e., limited cognitive capacity)
* Non-English speaking

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No